IRDiRC: 1000 new rare diseases treatments by 2027, identifying and bringing forward strategic actions

Abstract

In 2017, the International Rare Diseases Research Consortium (IRDiRC) set out ambitious goals, one of which specifically aimed to stimulate the development and approval of 1000 new therapies for rare diseases by 2027. This goal was part of IRDiRC’s concerted efforts to foster research and provide better diagnostics and care options for the estimated 400 million patients suffering from the more than 6000 rare diseases (RD) worldwide. Lack of therapeutic options for rare disease patients is an urgent issue. Treatments are estimated to be available for less than 6% of RD conditions, and fewer than 50 new therapies per year are approved by regulatory agencies worldwide, leaving a major discrepancy between patient needs and therapeutic solutions. This paper describes the recent key steps the IRDiRC Therapies Scientific Committee (TSC) has taken to support the future approval of 1000 new therapies, namely Step 1 (conducting a gap analysis of the rare diseases drug development landscape) and Step 2 (developing strategic themes to advance IRDiRC Goal 2 and act upon them). The IRDiRC TSC created a multi-stakeholder group to run a gap analysis of the RD drug development field. The analysis identified four main priority needs: (1) the definition of a new master plan for RD medicines suitable for all developers (large and small pharmaceutical companies, academics, and not-for-profit organizations) incorporating stakeholders’ perspectives and best practices in the field to increase efficiency in the development and registration of innovative drugs and generate more value for patients and the healthcare system; (2) the elicitation of a research framework and business model for repurposing of existing drugs for RD indications to enact a quantum enlargement of the existing therapeutic armamentarium; (3) the definition of standards and practices for data collection in healthcare practice and their implementation in drug development to provide real-world evidence; and (4) the re-focusing of the current international RD research agenda pushing for concentrated research efforts and funding in support of the development of future treatments. In addition to identifying where efforts should be put, the TSC has concretely contributed to advance the IRDiRC goal by creating tools (e.g., the Orphan Drug Development Guidebook) and recommendations and making them available to the whole RD community. However, much remains to be done, and the TSC has refined its approach to incorporate progress made and reflect on new challenges.

Keywords

IRDiRC / orphan drugs / orphan medicinal products / medicines development / gap analysis / rare diseases / rare diseases therapies / rare diseases treatments

References

[1] Dawkins HJS,Lasko P.International Rare Diseases Research Consortium (IRDiRC)Progress in rare diseases research 2010-2016: an IRDiRC perspective.Clin Transl Sci2018;11:11-20 PMCID:PMC5759730

[2] World Health Organization. Rare diseases - background paper. Available from: https://www.who.int/medicines/areas/priority_medicines/Ch6_19Rare.pdf [Last accessed on 20 Oct 2021]

[3] Orphanet. Orphanet report series - prevalence and incidence of rare diseases. Available from: https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf [Last accessed on 20 Oct 2021]

[4] Vision & Goals. Available from: https://irdirc.org/about-us/vision-goals/ [Last accessed on 20 Oct 2021]

[5] Austin CP,Lau LPL.International Rare Diseases Research Consortium (IRDiRC)Future of rare diseases research 2017-2027: an IRDiRC perspective.Clin Transl Sci2018;11:21-7 PMCID:PMC5759721

[6] IRDiRC. Therapies Scientific Committee (TSC). Available from: https://irdirc.org/about-us/people-organisation/scientific-committees/tsc/ [Last accessed on 20 Oct 2021]

[7] Orphan Drug Act - relevant excerpts. Available from: https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/orphan-drug-act-relevant-excerpts [Last accessed on 20 Oct 2021]

[8] European Commission. Regulation No 141/2000 of the European Parliament and of the Council on orphan medical products. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf [Last accessed on 20 Oct 2021]

[9] Boycott KM.Addressing challenges in the diagnosis and treatment of rare genetic diseases.Nat Rev Drug Discov2018;17:151-2

[10] RARE Facts. Global Genes. Available from: https://globalgenes.org/rare-disease-facts/ [Last accessed on 20 Oct 2021]

[11] Gahl WA,Hivert V,Zanello G.Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group.Orphanet J Rare Dis2021;16:308 PMCID:PMC8278724

[12] Day S,Lau LPL.Recommendations for the design of small population clinical trials.Orphanet J Rare Dis2018;13:195 PMCID:PMC6219020

[13] Morel T.Measuring what matters to rare disease patients - reflections on the work by the IRDiRC taskforce on patient-centered outcome measures.Orphanet J Rare Dis2017;12:171 PMCID:PMC5667521

[14] The innovation imperative: drug development. EIU Parexel. Available from: https://druginnovation.eiu.com/ [Last accessed on 20 Oct 2021]

[15] Hechtelt Jonker A,Gabaldo M.Boosting delivery of rare disease therapies: the IRDiRC Orphan Drug Development Guidebook.Nat Rev Drug Discov2020;19:495-6

[16] Malinowski KP,Trabka W,Pilc A.Reimbursement of orphan drugs in Europe in relation to the type of authorization by the European Medicines Agency and the Decision Making based on Health Technology Assessment.Front Pharmacol2018;9:1263 PMCID:PMC6240661

[17] Nicod E,Bucsics A,Upadhyaya S.HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries.Health Policy2019;123:140-51

[18] Precision Medicine. Available from: https://www.fda.gov/medical-devices/vitro-diagnostics/precision-medicine [Last accessed on 20 Oct 2021]

[19] IRDiRC Orphan Drug Development Guide. Available from: https://orphandrugguide.org/ [Last accessed on 20 Oct 2021]

[20] EJP RD - European Joint Programme on rare diseases. Available from: https://www.ejprarediseases.org/ [Last accessed on 20 Oct 2021]

[21] Orphan Drug Development Guidebook Materials. Available from: https://irdirc.org/orphan-drug-development-guidebook-materials/ [Last accessed on 20 Oct 2021]

[22] Southall NT,Lau LPL.IRDiRC Data Mining and Repurposing Task ForceThe use or generation of biomedical data and existing medicines to discover and establish new treatments for patients with rare diseases - recommendations of the IRDiRC Data Mining and Repurposing Task Force.Orphanet J Rare Dis2019;14:225 PMCID:PMC6794821

[23] DAUE R. Commission Expert Group on safe and timely access to medicines for patients (“STAMP”). Available from: https://ec.europa.eu/health/documents/pharmaceutical-committee/stamp_en [Last accessed on 20 Oct 2021]

[24] Drug repurposing screening for rare and neglected diseases. Available from: https://ncats.nih.gov/trnd/projects/drug-repurposing [Last accessed on 20 Oct 2021]